No Brexit Fall Out For UK FIH Trials With Over 40% Jump In Applications
Despite Brexit, the UK is still seen as an attractive place to do clinical research, according to the Medicines and Healthcare products Regulatory Agency. However, the agency's involvement in the EU Voluntary Harmonization Procedure has taken a hit.
You may also be interested in...
The UK insists there have been no major changes to the clinical trial environment since the country voted to leave the EU more than three years ago. It says the country continues to be an attractive location for clinical research.
The UK is revising its clinical trial processes to align them with the new EU Clinical Trials Regulation so that companies can seek authorization just as easily in the UK as in other EU member states, irrespective of the situation after Brexit.
The UK pharmaceutical industry has welcomed government guidance on the clinical trial regulatory landscape after Brexit, as well as a report from Cancer Research UK on the need to preserve alignment with the EU’s Clinical Trial Regulation.